Please login to the form below
Yervoy
This page shows the latest Yervoy news and features for those working in and with pharma, biotech and healthcare.
BMS’ Q2 results beat expectations with strong performance across core therapy areas
Sales of its oncology drugs Opdivo and Yervoy also increased on the same period last year, up by 16% and 38%, respectively.
Latest news
-
GSK discontinues two feladilimab trials in head and neck cancer
An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had previously been
-
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
BMS’ checkpoint inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced RCC patients. ... Today's milestone builds on our heritage of developing and delivering novel
-
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
Opdivo is already approved in combination with Yervoy (ipilimumab) as an initial treatment for advanced RCC patients, after the treatment showed an ability to improve survival compared to Sutent.
-
BMS gains FDA approval for second Opdivo combo in kidney cancer
BMS' Opdivo/Yervoy regimen was its first combo to be approved for advanced renal cell carcinoma. ... BMS’ PD-L1 inhibitor Opdivo (nivolumab) is already approved in combination with CTLA-4 inhibitor Yervoy (ipilimumab) as an initial treatment for
-
BMS aims for US approval of Opdivo combo in stomach cancer
inhibitor Yervoy (Ipilimumab). ... That includes an approval from the European Commission (EC) in June 2020 for Opdivo plus Yervoy alongside two cycles of chemotherapy for the first-line treatment of adults with metastatic NSCLC,
More from news
Approximately 37 fully matching, plus 151 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better long-term survival than the Keytruda/chemotherapy combination which is driving the growth
-
Encouraging signs in biomarker R&D
In June 2018, Bristol Myers-Squibb sought approval for Opdivo and low-dose Yervoy in lung cancer in patients with a TMB of greater than ten mutations per megabase. ... impact of Opdivo plus Yervoy on OS in first-line NSCLC patients’.
-
Cancer immunotherapy: What's on the horizon?
drug Yervoy (ipilimumab) in an early-stage trial.
-
Pharma deals in February 2015
As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
-
Pharma deals during July 2014
In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
CytomX appoints Rachel Humphrey chief medical officer
drug Yervoy (ipilimumab).
-
Jonathan Dickinson joins Ariad from BMS
population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
Immunotherapy in oncology
This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II
-
Video: Immuno-oncology therapies
However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.
-
Video: Immuno-oncology therapies
However, these therapies come with a very high price tag and currently only a few of these drugs have actually reached the market including Opdivo, Keytruda and Yervoy.
-
ASCO 2015: What you missed in Chicago
In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- EIT Health and Biogen announce winners of first ‘neurotechprize’
- Scientists discover new approach to treat brain tumours
- Roche reinforces commitment to the World Federation of Hemophilia Humanitarian Aid Program
- UK trial of fourth vaccine dose shows increased protection against COVID-19
- Biogen and Eisai announce FDA submission for early Alzheimer’s treatment
- BMA appoints two internal candidates to share the role of chief executive officer
- Almirall and Inserm Transfert to develop innovative vitiligo treatments
- Recognising HIV Vaccine Awareness Day
- AstraZeneca and UK-based biotech company RQ BIO sign licencing agreement
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- How scientific storytelling can help Pharma cut through the noise
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- GSK accused of delaying generic Seroxat in UK
- Christian Schade joins Aprea AB
- Assessing the value of interim analyses in clinical trials
- MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
- Serious about sustainability?
- Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
- How scientific storytelling can help Pharma cut through the noise
- Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...
